Outcome and safety of SBRT in centrally and ultra-centrally located lung tumours: A PRISMA-based systematic review and Meta-Analysis.
메타분석
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
509 patients with central and ultra-central lung tumours.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
0.12% [range: 0 - 7.09; CI 95% = 0.00 - 0.46]. [CONCLUSION] SBRT with 60 Gy in 8 fractions provides a feasible and safe curative treatment approach for patients with centrally and ultra-centrally located lung tumours.
OpenAlex 토픽 ·
Lung Cancer Diagnosis and Treatment
Hepatocellular Carcinoma Treatment and Prognosis
Lung Cancer Research Studies
[INTRODUCTION] Stereotactic Body Radiation Therapy (SBRT) offers a curative treatment option for patients with early-stage central and ultra-central lung tumours, however can be associated with severe
APA
Shari Wiegreffe, Sonja Adebahr, et al. (2026). Outcome and safety of SBRT in centrally and ultra-centrally located lung tumours: A PRISMA-based systematic review and Meta-Analysis.. Clinical and translational radiation oncology, 59, 101151. https://doi.org/10.1016/j.ctro.2026.101151
MLA
Shari Wiegreffe, et al.. "Outcome and safety of SBRT in centrally and ultra-centrally located lung tumours: A PRISMA-based systematic review and Meta-Analysis.." Clinical and translational radiation oncology, vol. 59, 2026, pp. 101151.
PMID
41953588
Abstract
[INTRODUCTION] Stereotactic Body Radiation Therapy (SBRT) offers a curative treatment option for patients with early-stage central and ultra-central lung tumours, however can be associated with severe side effects. This review provides a structured quantitative evaluation of outcomes and safety in these critical locations, therefore offering safety-oriented evidence to support individualised treatment planning.
[METHODS] Pubmed/MEDLINE was searched with the term ["Carcinoma, Non-Small-Cell Lung"[Mesh] AND ("Radiosurgery"[Mesh] OR "SABR" OR "stereotactic ablative radiotherapy" OR "SBRT" OR "stereotactic body radiotherapy")] according to PRISMA-guidelines. Trials reporting on SBRT in central and ultra-central lung tumours and on outcome parameters were included. A -analysis of proportions was performed using random-effect models.
[RESULTS] 57 retrospective and 12 prospective trials were included, encompassing in total 3,672 and 1,509 patients with central and ultra-central lung tumours. The median follow-up was 22.7 (range: 10.6 - 93.6) months for centrally and 21.2 (8.6 - 93.6) months for ultra-centrally located tumours. For ultra-central lesions the median overall survival was 28.0 (12.0 - 64.5) months compared to 39.4 (19.0 - 57.0) months in central lesions with highest efficacy of SBRT with 60 Gy in 8 fractions. Overall, pooled grade 3-5 toxicity was low for both localizations. The most frequently reported fatal complication in ultra-centrally vs. centrally located tumours was haemorrhage with an estimated proportion of 0.48% [range: 0 - 14.89; CI 95% = 0.00 - 1.68] vs. 0.12% [range: 0 - 7.09; CI 95% = 0.00 - 0.46].
[CONCLUSION] SBRT with 60 Gy in 8 fractions provides a feasible and safe curative treatment approach for patients with centrally and ultra-centrally located lung tumours.
[METHODS] Pubmed/MEDLINE was searched with the term ["Carcinoma, Non-Small-Cell Lung"[Mesh] AND ("Radiosurgery"[Mesh] OR "SABR" OR "stereotactic ablative radiotherapy" OR "SBRT" OR "stereotactic body radiotherapy")] according to PRISMA-guidelines. Trials reporting on SBRT in central and ultra-central lung tumours and on outcome parameters were included. A -analysis of proportions was performed using random-effect models.
[RESULTS] 57 retrospective and 12 prospective trials were included, encompassing in total 3,672 and 1,509 patients with central and ultra-central lung tumours. The median follow-up was 22.7 (range: 10.6 - 93.6) months for centrally and 21.2 (8.6 - 93.6) months for ultra-centrally located tumours. For ultra-central lesions the median overall survival was 28.0 (12.0 - 64.5) months compared to 39.4 (19.0 - 57.0) months in central lesions with highest efficacy of SBRT with 60 Gy in 8 fractions. Overall, pooled grade 3-5 toxicity was low for both localizations. The most frequently reported fatal complication in ultra-centrally vs. centrally located tumours was haemorrhage with an estimated proportion of 0.48% [range: 0 - 14.89; CI 95% = 0.00 - 1.68] vs. 0.12% [range: 0 - 7.09; CI 95% = 0.00 - 0.46].
[CONCLUSION] SBRT with 60 Gy in 8 fractions provides a feasible and safe curative treatment approach for patients with centrally and ultra-centrally located lung tumours.